Prof. Alper OKYAR

Publication Network

Articles 74

1. Effects of everolimus on circadian gene expression and cell fate in synchronized Caco-2 cells

ÖZTÜRK CİVELEK D., GÖNCÜ B. S., Goncu S., OKYAR A.

Experimental Cell Research , vol.453, no.2, 2025 (SCI-Expanded, Scopus)

2. Identification of potential SARS-CoV-2 inhibitors among well-tolerated drugs using drug repurposing and in vitro approaches

Oruçoğlu B., Çetin İ., Şimşek H., Topçul M. R., Çalışkan M., Aydın C., et al.

SCIENTIFIC REPORTS , vol.15, no.1, 2025 (SCI-Expanded)

3. Chrono-immunotherapy as a low-hanging fruit for cancer treatment? A call for pragmatic randomized clinical trials

Özdemir B. C., Bill R., OKYAR A., Scheiermann C., Hayoz S., Olivier T.

Journal for immunotherapy of cancer , vol.13, no.3, 2025 (SCI-Expanded)

4. **The impact of circadian rhythm disruption on oxaliplatin tolerability and pharmacokinetics in Cry1^-/-Cry2^-/- mice under constant darkness**

AKYEL Y. K., Seyhan N. O., Gul S., Celik M., TAŞKIN A. C., Selby C. P., et al.

ARCHIVES OF TOXICOLOGY , 2025 (SCI-Expanded)

5. Dosing-time, feeding, and sex-dependent variations of everolimus pharmacokinetics in mice

Ozturk Civelek D., Ozturk Seyhan N., Akyel Y. K., Gazioglu I., Pala Kara Z., Orman M. N., et al.

FUNDAMENTAL & CLINICAL PHARMACOLOGY , vol.38, no.5, pp.883-896, 2024 (SCI-Expanded) Sustainable Development

6. A new validated high-performance liquid chromatography method for the determination of regorafenib in rat plasma: Application for pharmacokinetic study

AYDOĞMUŞ Z., Yilmaz E. M., ÖZTÜRK SEYHAN N., OKYAR A.

SEPARATION SCIENCE PLUS , vol.7, no.6, 2024 (ESCI)

7. Circadian Regulation of Drug Responses: Toward Sex-Specific and Personalized Chronotherapy

Lévi F. A., Okyar A., Hadadi E., Innominato P. F., Ballesta A.

ANNUAL REVIEW OF PHARMACOLOGY AND TOXICOLOGY , vol.64, pp.89-114, 2024 (SCI-Expanded) Sustainable Development

8. The role of the circadian timing system on drug metabolism and detoxification: an update

OKYAR A., ÖZTÜRK CİVELEK D., AKYEL Y. K., Surme S., PALA KARA Z., Kavakli İ. H.

Expert Opinion on Drug Metabolism and Toxicology , vol.20, no.6, pp.503-517, 2024 (SCI-Expanded)

9. TW68, cryptochromes stabilizer, regulates fasting blood glucose levels in diabetic ob/ob and high fat-diet-induced obese mice

Surme S., Ergun C., Gul S., AKYEL Y. K., Gul Z. M., Ozcan O., et al.

BIOCHEMICAL PHARMACOLOGY , vol.218, 2023 (SCI-Expanded) Sustainable Development

10. Induction of humoral and cell-mediated immunity in mice by chitosan-curdlan composite nanoparticles administered intranasally and subcutaneously

SESSEVMEZ M., Sinani G., OKYAR A., Alpar H. O., CEVHER E.

JOURNAL OF DRUG DELIVERY SCIENCE AND TECHNOLOGY , vol.86, 2023 (SCI-Expanded) Sustainable Development

11. Circadian Dysfunction in Adipose Tissue: Chronotherapy in Metabolic Diseases

CİVELEK E., ÖZTÜRK CİVELEK D., AKYEL Y. K., KALELİ DURMAN D., OKYAR A.

Biology , vol.12, no.8, 2023 (SCI-Expanded, Scopus)

12. Therapeutic Effect of C-Vx Substance in K18-hACE2 Transgenic Mice Infected with SARS-CoV-2

Polat H. U., Abaci I., Tas Ekiz A., Aksoy O., ÖKTELİK F. B., YILMAZ V., et al.

INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES , vol.24, no.15, 2023 (SCI-Expanded, Scopus)

13. Modulation of monepantel secretion into milk by soy isoflavones

GÜNEŞ Y., Okyar A., Krajcsi P., Fekete Z., ÜSTÜNER O.

JOURNAL OF VETERINARY PHARMACOLOGY AND THERAPEUTICS , vol.46, no.3, pp.185-194, 2023 (SCI-Expanded) Sustainable Development

14. Diurnal Changes in Capecitabine Clock-Controlled Metabolism Enzymes Are Responsible for Its Pharmacokinetics in Male Mice

Akyel Y. K., Ozturk Civelek D., Ozturk Seyhan N., Gul Ş., Gazioglu I., Pala Kara Z., et al.

JOURNAL OF BIOLOGICAL RHYTHMS , vol.38, no.2, pp.171-184, 2023 (SCI-Expanded)

15. The effect of biocompatible carriers with vitamin D and platelet-rich plasma (PRP) on bone defects

Turgut C. T., Civelek D. O., KOTİL T., GÜNGÖR S., Ozsoy Y., Dirican A., et al.

HIPPOKRATIA , vol.27, no.2, pp.48-56, 2023 (SCI-Expanded)

16. **Discovery of a small molecule that selectively destabilizes Cryptochrome 1 and enhances life span in p53 knockout mice**

Gul Ş., Akyel Y. K., Gul Z. M., Isin S., Ozcan O., Korkmaz T., et al.

NATURE COMMUNICATIONS , vol.13, no.1, 2022 (SCI-Expanded) Sustainable Development

17. Dosing-time dependent testicular toxicity of everolimus in mice

Ozturk N., Civelek D. O., Sancar S., Kaptan E., Kara Z., Okyar A.

EUROPEAN JOURNAL OF PHARMACEUTICAL SCIENCES , vol.165, 2021 (SCI-Expanded, Scopus) Sustainable Development

18. In silico identification of widely used and well-tolerated drugs as potential SARS-CoV-2 3C-like protease and viral RNA-dependent RNA polymerase inhibitors for direct use in clinical trials

Gul Ş., Ozcan O., Asar S., OKYAR A., Baris I., Kavakli I. H.

JOURNAL OF BIOMOLECULAR STRUCTURE & DYNAMICS , vol.39, no.17, pp.6772-6791, 2021 (SCI-Expanded) Sustainable Development

19. The effects of P-glycoprotein inhibitor zosuquidar on the sex and time-dependent pharmacokinetics of parenterally administered talinolol in mice

Pala K., Ozturk C., Ozturk N., Okyar A.

EUROPEAN JOURNAL OF PHARMACEUTICAL SCIENCES , vol.156, 2021 (SCI-Expanded)

20. The Association of ABCC5 and ABCC11 Polymorphisms with The Pharmacokinetics of 5-FU in Advanced Gastric Cancer Patients

Kara Z., Oztas E., ÖZTÜRK D., Akyel Y. K., Turna H., Okyar A., et al.

CLINICAL AND EXPERIMENTAL HEALTH SCIENCES , vol.10, no.3, pp.285-291, 2020 (ESCI) Sustainable Development

21. Reproductive effects of subchronic exposure to acetamiprid in male rats

Arıcan E., Gökçeoğlu K., Ulus K., Boran T., Öztürk N., Okyar A., et al.

SCIENTIFIC REPORTS , vol.10, no.1, 2020 (SCI-Expanded, Scopus)

22. Effects of atorvastatin on talinolol absorption: A potential drug-drug interaction.

Kara Z., Ozturk D., Ozturk N., Orman M., Baktir G., Okyar A.

Die Pharmazie , vol.75, pp.70-74, 2020 (SCI-Expanded)

23. A CLOCK-binding small molecule disrupts the interaction between CLOCK and BMAL1 and enhances circadian rhythm amplitude.

Doruk Y., Yarparvar D., Akyel Y., Gul Ş., Taskin A. C., Yilmaz F., et al.

The Journal of biological chemistry , vol.295, no.11, pp.3518-3531, 2020 (SCI-Expanded)

24. Toxic effects of subchronic oral acetamiprid exposure in rats

Karaca B. U., Arican Y. E., Boran T., Binay S., Okyar A., Kaptan E., et al.

TOXICOLOGY AND INDUSTRIAL HEALTH , vol.35, pp.679-687, 2019 (SCI-Expanded, Scopus)

25. Evaluation of the association of SNP in carboxylesterase enzyme (CES1) with pharmacokinetic and adverse effects of capecitabine in breast and colorectal cancer patients

Yuksel M. K., ÖZTÜRK D., Oztas E., Ozhan G., Turker A. A., KORKMAZ T., et al.

ISTANBUL JOURNAL OF PHARMACY , vol.49, no.2, pp.64-69, 2019 (ESCI) Sustainable Development

26. Sex-, feeding-, and circadian time-dependency of P-glycoprotein expression and activity - implications for mechanistic pharmacokinetics modeling.

Okyar A., Kumar S. A., Filipski E., Piccolo E., Ozturk N., Xandri-Monje H., et al.

Scientific reports , vol.9, pp.10505, 2019 (SCI-Expanded)

27. Gliclazide alone or in combination with atorvastatin ameliorated reproductive damage in streptozotocin-induced type 2 diabetic male rats

Oztas E., YILMAZ T. E., GUZEL E., SEZER Z., Okyar A., Ozhan G.

SAUDI PHARMACEUTICAL JOURNAL , vol.27, no.3, pp.422-431, 2019 (SCI-Expanded, Scopus) Sustainable Development

28. The immune system as a chronotoxicity target of the anticancer mTOR inhibitor everolimus

Ozturk N., Öztürk D., Pala-Kara Z., Kaptan E., Sancar-Bas S., Ozsoy N., et al.

Chronobiology International , vol.35, pp.705-718, 2018 (SCI-Expanded, Scopus) Sustainable Development

29. Molecular Aspects of Circadian Pharmacology and Relevance for Cancer Chronotherapy

Ozturk N., Ozturk D., Kavakli I. H., Okyar A.

INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES , vol.18, no.10, 2017 (SCI-Expanded) Sustainable Development

30. Nasal vaccination with poly(β-amino ester)-poly(d,l-lactide-co-glycolide) hybrid nanoparticles.

SINANI G., Sessevmez M., Koray G., Özgümüş S., Okyar A., Oya A., et al.

International journal of pharmaceutics , vol.529, pp.1-14, 2017 (SCI-Expanded) Sustainable Development

31. Türkiye denizlerinde zehirli denizanaları ve toksik etkileri (Venomous jellyfishes in the Turkish seas and their toxic effects).

İŞİNİBİLİR OKYAR M., OKYAR A., ÖZTÜRK N.

Turkish Journal of Aquatic Sciences , vol.32, no.3, pp.154-169, 2017 (Peer-Reviewed Journal)

32. Critical cholangiocarcinogenesis control by cryptochrome clock genes

Mteyrek A., Filipski E., GUETTIER C., OKLEJEWICZ M., VAN DER HORST G. T. J., Okyar A., et al.

INTERNATIONAL JOURNAL OF CANCER , vol.140, no.11, pp.2473-2483, 2017 (SCI-Expanded) Sustainable Development

33. Pharmacokinetics of talinolol is modified by barnidipine: implication of P-glycoprotein modulation

Ozturk N., Öztürk D., Pala-Kara Z., Okyar A.

PHARMAZIE , vol.72, no.1, pp.29-34, 2017 (SCI-Expanded)

34. Clock gene Per2 as a controller of liver carcinogenesis

Mteyrek A., Filipski E., GUETTIER C., Okyar A., Levi F.

ONCOTARGET , vol.7, no.52, pp.85832-85847, 2016 (SCI-Expanded) Sustainable Development

35. Chronomodulated oxaliplatin plus Capecitabine (XELOX) as a first line chemotherapy in metastatic colorectal cancer: A Phase II Brunch regimen study

PILANCI K. N., Saglam S., Okyar A., YÜCEL S., Pala-Kara Z., Ordu C., et al.

CANCER CHEMOTHERAPY AND PHARMACOLOGY , vol.78, no.1, pp.143-150, 2016 (SCI-Expanded) Sustainable Development

36. Carbon tetrachloride-induced kidney damage and protective effect of Amaranthus lividus L. in rats

Yilmaz-Ozden T., Can A., Karatug A., Pala-Kara Z., Okyar A., Bolkent S.

TOXICOLOGY AND INDUSTRIAL HEALTH , vol.32, no.6, pp.1143-1152, 2016 (SCI-Expanded)

37. Dosing-Time Makes the Poison: Circadian Regulation and Pharmacotherapy

Dallmann R., Okyar A., Leyi F.

TRENDS IN MOLECULAR MEDICINE , vol.22, no.5, pp.430-445, 2016 (SCI-Expanded)

38. THE PROTECTIVE EFFECT OF AN AQUEOUS EXTRACT FROM SMILAX EXCELSA L. AGAINST CARBON TETRACHLORIDE-INDUCED LIVER INJURY IN RATS

Ozsoy N., Okyar A., Arda-Pirincci P., Can A., Bolkent Ş., Akev N.

AFRICAN JOURNAL OF TRADITIONAL COMPLEMENTARY AND ALTERNATIVE MEDICINES , vol.13, no.3, pp.203-208, 2016 (SCI-Expanded)

39. Preparation and in-vivo evaluation of dimenhydrinate buccalmucoadhesive films with enhanced bioavailability

Pekoz A., Erdal M. S., Okyar A., Ocak M., Tekeli F., Kaptan E., et al.

Drug Development and Industrial Pharmacy , vol.42, no.6, pp.916-925, 2016 (SCI-Expanded)

40. Identification of Circadian Determinants of Cancer Chronotherapy through In Vitro Chronopharmacology and Mathematical Modeling

Dulong S., Ballesta A., Okyar A., Levi F.

MOLECULAR CANCER THERAPEUTICS , vol.14, no.9, pp.2154-2164, 2015 (SCI-Expanded) Sustainable Development

41. Protective effect of Amaranthus lividus L. on carbon tetrachloride induced hepatotoxicity in rats

Yilmaz-Ozden T., Can A., Sancar-Bas S., Pala-Kara Z., Okyar A., Bolkent Ş.

TURKISH JOURNAL OF BIOCHEMISTRY-TURK BIYOKIMYA DERGISI , vol.40, no.2, pp.125-131, 2015 (SCI-Expanded)

42. Neoadjuvant chronomodulated capecitabine with radiotherapy in rectal cancer: a phase II brunch regimen study

Akgun Z., Saglam S., YÜCEL S., Gural Z., Balik E., Cipe G., et al.

CANCER CHEMOTHERAPY AND PHARMACOLOGY , vol.74, no.4, pp.751-756, 2014 (SCI-Expanded) Sustainable Development

43. Optimization of irinotecan chronotherapy with P-glycoprotein inhibition

Filipski E., Berland E., Ozturk N., GUETTIER C., VAN DER HORST G. T. J., Levi F., et al.

TOXICOLOGY AND APPLIED PHARMACOLOGY , vol.274, no.3, pp.471-479, 2014 (SCI-Expanded)

44. Evaluation of Smilax excelsa L. Use in Experimentally Induced Nephrotoxicity

Ozsoy N., Okyar A., Arda-Pirincci P., Can A., Bolkent S., Akev N.

KAFKAS UNIVERSITESI VETERINER FAKULTESI DERGISI , vol.19, pp.807-814, 2013 (SCI-Expanded)

45. The effect of repeated administration of methotrexate (MTX) on rat ovary: measurement of serum antimullerian hormone (AMH) levels

Benian A., Guralp O., Uzun D. D., Okyar A., Sahmay S.

GYNECOLOGICAL ENDOCRINOLOGY , vol.29, no.3, pp.226-229, 2013 (SCI-Expanded)

46. ABC transporters: circadian rhythms and sexrelated differences

Kara Z. P., ÖZTÜRK N., Ozturk D., OKYAR A.

CLINICAL AND EXPERIMENTAL HEALTH SCIENCES , vol.3, no.1, pp.1-13, 2013 (ESCI) Sustainable Development

47. Circadian Variations in Exsorptive Transport: In Situ Intestinal Perfusion Data and In Vivo Relevance

Okyar A., Dressler C., Hanafy A., Baktir G., Lemmer B., Spahn-Langguth H.

CHRONOBIOLOGY INTERNATIONAL , vol.29, no.4, pp.443-453, 2012 (SCI-Expanded)

48. Circadian clocks and drug delivery systems: impact and opportunities in chronotherapeutics

Levi F., Okyar A.

EXPERT OPINION ON DRUG DELIVERY , vol.8, no.12, pp.1535-1541, 2011 (SCI-Expanded) Sustainable Development

49. A Combined Experimental and Mathematical Approach for Molecular-based Optimization of Irinotecan Circadian Delivery

Ballesta A., Dulong S., Abbara C., Cohen B., Okyar A., Clairambault J., et al.

PLOS COMPUTATIONAL BIOLOGY , vol.7, no.9, 2011 (SCI-Expanded) Sustainable Development

50. Strain- and Sex-Dependent Circadian Changes in Abcc2 Transporter Expression: Implications for Irinotecan Chronotolerance in Mouse Ileum

Okyar A., Piccolo E., Ahowesso C., Filipski E., Hossard V., Guettier C., et al.

PLOS ONE , vol.6, no.6, 2011 (SCI-Expanded)

51. The Effect of Terpenes on Percutaneous Absorption of Tiaprofenic Acid Gel

Okyar A., Nuriyev M., Yildiz A., Pala-Kara Z., Ozturk N., Kaptan E.

ARCHIVES OF PHARMACAL RESEARCH , vol.33, no.11, pp.1781-1788, 2010 (SCI-Expanded)

52. ATP-Binding Cassette B1 Transports Seliciclib (R-Roscovitine), a Cyclin-Dependent Kinase Inhibitor

RAJNAI Z., Mehn D., BEERY E., Okyar A., Jani M., Toth G. K., et al.

DRUG METABOLISM AND DISPOSITION , vol.38, no.11, pp.2000-2006, 2010 (SCI-Expanded) Sustainable Development

53. Ondansetron-loaded chitosan microspheres for nasal antiemetic drug delivery: an alternative approach to oral and parenteral routes

Gungor S., Okyar A., Erturk-Toker S., Baktir G., Ozsoy Y.

DRUG DEVELOPMENT AND INDUSTRIAL PHARMACY , vol.36, no.7, pp.806-813, 2010 (SCI-Expanded)

54. Ondansetron-loaded biodegradable microspheres as a nasal sustained delivery system: In vitro/in vivo studies

Gungor S., Okyar A., Erturk-Toker S., Baktir G., Ozsoy Y.

PHARMACEUTICAL DEVELOPMENT AND TECHNOLOGY , vol.15, no.3, pp.258-265, 2010 (SCI-Expanded)

55. Nasal administration of ciprofloxacin loaded chitosan microspheres: in vitro and in vivo evaluation

Gürcan D., OKYAR A., Karakoç B., Gerçeker A., Baktır G., ÖZSOY Y.

Acta Pharmaceutica Sciencia , vol.52, pp.5-18, 2010 (Scopus)

56. Circadian Timing in Cancer Treatments

Levi F., Okyar A., Dulong S., Innominato P. F., Clairambault J.

ANNUAL REVIEW OF PHARMACOLOGY AND TOXICOLOGY , vol.50, pp.377-421, 2010 (SCI-Expanded) Sustainable Development

57. Self-management of complications in diabetic patients: a pharmaceutical care program in community pharmacies

Koroglu A., Cakiroglu A., Almila-Oztosun Z., Dundar A., Alp F. I., Okyar A., et al.

PHARMACY WORLD & SCIENCE , vol.30, no.5, pp.657, 2008 (SCI-Expanded) Sustainable Development

58. Pre-diabetes screening program: a proactive study in Istanbul community pharmacies

Cakiroglu A., Koroglu A., Almila-Oztosun Z., Dundar A., Okyar A., Alp F. I., et al.

PHARMACY WORLD & SCIENCE , vol.30, no.5, pp.717, 2008 (SCI-Expanded) Sustainable Development

59. Effect of terpenes as penetration enhancers on percutaneous penetration of tiaprofenic acid through pig skin.

Yıldız Peköz A., Okyar A., Baktır G., Özsoy Y.

ACTA PHARMACEUTICA SCIENCIA , vol.50, no.3, pp.247, 2008 (Scopus)

60. Effectiveness of Aloe vera versus glibenclamide on serum lipid parameters, heart and skin lipid peroxidation in type-II diabetic rats

Ozsoy N., Yanardag R., Can A., Akev N., Okyar A.

ASIAN JOURNAL OF CHEMISTRY , vol.20, no.4, pp.2679-2689, 2008 (SCI-Expanded) Sustainable Development

61. In Vitro and Ex Vivo permeation studies of etodolac from hydrophilic gels and effect of Terpenes as enhancers

Taş C., Özkan Y., Okyar A., Savaşer A.

DRUG DELIVERY , vol.14, no.7, pp.453-459, 2007 (SCI-Expanded)

62. The effect of cetirizine on psychomotor performance in healthy volunteers

OKYAR A., Baktır G.

J Fac Pharm Istanbul (İstanbul Ecz Fak Mec) , vol.50, no.3, pp.247-0, 2006 (Peer-Reviewed Journal)

63. Nasal administration of heparin-loaded microspheres based on poly(lactic acid)

Yildiz A., Okyar A., Baktir G., Araman A., Özsoy Y.

Farmaco , vol.60, pp.919-924, 2005 (SCI-Expanded)

64. THE EFFECTS OF CETIRIZINE ON PSYCHOMOTOR PERFORMANCE IN HEALTHY VOLUNTEERS

Okyar A., Baktir G.

ISTANBUL JOURNAL OF PHARMACY , vol.38, no.1, pp.103-108, 2005 (ESCI)

65. Immunohistochemical studies on the effect of Aloe vera on the pancreatic beta-cells in neonatal streptozotocin-induced type-II diabetic rats

Bolkent Ş., Akev N., Can A., Bolkent H. S., Yanardağ R., Okyar A.

Egyptian Journal of Biology , vol.7, pp.14-19, 2005 (Peer-Reviewed Journal)

66. Effect of aloe vera leaf gel and pulp extracts on the liver in type-II diabetic rat models

Can A., Akev N., Ozsoy N., Bolkent S., Arda B. P., Yanardag R., et al.

BIOLOGICAL & PHARMACEUTICAL BULLETIN , vol.27, no.5, pp.694-698, 2004 (SCI-Expanded) Sustainable Development

67. Effect of Aloe vera (L.) Burm. fil. leaf gel and pulp extracts on kidney in type-II diabetic rat models

BOLKENT Ş., AKEV N., ÖZSOY N., Şengezer-Inceli M., Can A., OKYAR A., et al.

Indian Journal of Experimental Biology , vol.42, no.1, pp.48-52, 2004 (Scopus)

68. The effect of Aloe vera (L.) Burm. fil. on the antioxidant system in lenses of type-II diabetic rats.

Özsoy N., Yanardağ R., Can A., Akev N., Okyar A.

İstanbul Eczacılık Fakültesi Mecmuası , vol.36, pp.83-88, 2003 (Peer-Reviewed Journal)

69. The effect of Aloe vera (L) Burm. Fil. on the antioxidant system in lenses of type-II diabetic rats

Ozsoy N., YANARDAĞ R., Can A., Akev N., Okyar A.

Journal of Faculty of Pharmacy of Istanbul , vol.35-36, pp.83-88, 2002 (Peer-Reviewed Journal) Sustainable Development

70. Drug-drug interactions with P-glycoprotein substrates: Mechanism for talinolol AUC increase different for p.o. and i.v. vinblastine coadministration?

Okyar A., Hanafy A., Baktir G., Spahn-Langguth H.

NAUNYN-SCHMIEDEBERGS ARCHIVES OF PHARMACOLOGY , vol.363, no.4, 2001 (SCI-Expanded)

71. Effect of Aloe vera leaves on blood glucose level in type I and type II diabetic rat models

Okyar A., Can A., Akev N., BAKTIR G., Sutlupinar N.

PHYTOTHERAPY RESEARCH , vol.15, no.2, pp.157-161, 2001 (SCI-Expanded) Sustainable Development

72. Aloe vera yapraklarının tip II diabetik sıçanların kan şekeri düzeyine etkisi (kronik deneyler).

OKYAR A., CAN A., AKEV N., Baktır G., SÜTLÜPINAR N.

XIII. Bitkisel İlaç Hammaddeleri Toplantısı, Bildiri Kitabı, Marmara Üniv. Yayın No. 670, Ecz. Fak. Yayın No , vol.1, pp.281-286, 2001 (Peer-Reviewed Journal) Sustainable Development

73. P-glycoprotein transporters and the gastrointestinal tract: Evaluation of the potential in vivo relevance of in vitro data employing talinolol as model compound

Spahn-Langguth H., Baktir G., Radschuweit A., Okyar A., Terhaag B., Ader P., et al.

INTERNATIONAL JOURNAL OF CLINICAL PHARMACOLOGY AND THERAPEUTICS , vol.36, no.1, pp.16-24, 1998 (SCI-Expanded)

74. Synthesis of new 2-arylidene-2H-1,4-benzoxazin-3(4H)-ones

GEZGINCI H., SALMAN S., Okyar A., BAKTIR G.

FARMACO , vol.52, no.4, pp.255-256, 1997 (SCI-Expanded)

Papers Presented at Peer-Reviewed Scientific Conferences 90

1. M47 Molekülünün Sıçanda Maksimum Tolere Edilebilir Dozunun (MTD) Araştırılması

İyigün B., Taşkın A. C., Öztürk Civelek D., Çevik A., Kaptan E., Kavaklı İ. H., et al.

5.Ulusal Laboratuvar Hayvanları Bilimi Kongresi, İstanbul, Turkey, 14 - 16 September 2023, pp.189-190, (Summary Text)

2. Effect of CLK8 on rhythmic transcriptome and replicative senescence in MRC-5 cells and further in vivo analysis

Gül Ş., Okyar A., Kavakli I. H.

11th International Drug Chemistry Conference, Antalya, Turkey, 9 - 12 March 2023, (Unpublished) Sustainable Development

3. Hidroksiklorokin’in P-glikoprotein substratı talinololün farmakokinetiğine etkisi

Sakbani S., Öztürk Civelek D., Okyar A., Pala Kara Z.

26. Ulusal, 1. Uluslararası Farmakoloji Kongresi, Ankara, Turkey, 4 - 06 November 2021, (Summary Text)

4. Dosing-time dependent pharmacokinetics of capecitabine and its metabolites in male mice

Akyel Y. K., Öztürk Civelek D., Öztürk Seyhan N., Gazioğlu I., Pala Kara Z., Kavaklı İ. H., et al.

26. Ulusal, 1. Uluslararası Farmakoloji Kongresi, Ankara, Turkey, 04 November 2021, (Summary Text)

5. Dosing-time and cryptochrome dependent changes in oxaliplatin tolerability and pharmacokinetics

Öztürk Seyhan N., Akyel Y. K., Gül Ş., Çelik M., Taşkın A. C., Sancar A., et al.

26th National and 1st International Pharmacology Congress, 10th Clinical Pharmacology Symposium, 9th Clinical Toxicology Symposium, İstanbul, Turkey, 4 - 06 November 2021, pp.280-281, (Summary Text)

6. Dosing-Time Dependent Pharmacokietics of Capecitabine and Its Metabolites in Male Mice.

Akyel Y. K., Öztürk Civelek D., Öztürk Seyhan N., Gazioğlu I., Pala Kara Z., Kavaklı İ. H., et al.

26th National and 1st International Pharmacology Congress, 10th Clinical Pharmacology Symposium, 9th Clinical Toxicology Symposium, İstanbul, Turkey, 4 - 06 November 2021, pp.278, (Summary Text)

7. mTOR İnhibitörü Everolimusun Yaşa Bağlı Farmakokinetiği

ÖZTÜRK F., AKYEL Y. K., ÖZTÜRK D., ÖZTÜRK N., PALA KARA Z., OKYAR A.

25. Ulusal Farmakoloji Kongresi, İzmir, Turkey, 3 - 07 November 2019, (Summary Text)

8. Circadian and sex-dependent pharmacokinetics of everolimus and implications of chronotherapy

Ozturk D., ÖZTÜRK N., Akyel Y. K., PALA KARA Z., OKYAR A.

XVI Congress of the European Biological Rhythms Society, Lyon, France, 25 - 29 August 2019, pp.100, (Full Text)

9. Circadian control of P-glycoprotein in Hepa1-6 hepatocarcinoma tumor cells and Hepa1-6 tumor-bearing mice.

ÖZTÜRK N., Dulong S., Li X., Levi F., OKYAR A.

18th World Congress of Basic and Clinical pharmacology (WCP2018), Kyoto, Japan, 1 - 06 July 2018, pp.19, (Full Text)

10. İstanbul Üniversitesi Eczacılık Fakültesi Farmakoloji Anabilim Dalının Hasta Odaklı Lisans Eğitim Programı

ALP YILDIRIM F. İ., OKYAR A., Topal Tanyılmaz G., KALELİ DURMAN D., PALA KARA Z., ÇARÇAK YILMAZ N., et al.

II. Ulusal Eczacılık eğitimi ve Akreditasyon Kongresi, Eskişehir, Turkey, 10 - 11 May 2016, pp.24, (Summary Text)

11. İstanbul Üniversitesi Eczacılık Fakültesi Farmakoloji Anabilim Dalı’nın yürüttüğü Hasta Odaklı Eğitimin Öğrenci Geri Bildirimleri ile Değerlendirilmesi

ALP YILDIRIM F. İ., OKYAR A., Topal Tanyılmaz G., KALELİ DURMAN D., PALA KARA Z., ÇARÇAK YILMAZ N., et al.

II. Ulusal Eczacılık eğitimi ve Akreditasyon Kongresi, Eskişehir, Turkey, 10 - 11 May 2016, pp.23, (Summary Text)

12. Relationship between everolimus chronotoxicity and rhythms of P-glycoprotein expression in Mdr1a::Luc mice.

ÖZTÜRK N., Li X., Giacchetti S., Levi F., OKYAR A.

International Meeting on Education & Research in Health Sciences 2017 (IMER-HS 2017), İstanbul, Turkey, 3 - 05 November 2017, pp.19, (Full Text)

13. mTOR inhibitörü everolimusun sirkadiyan saat sistemi üzerine etkisi ve farelerdeki kronotoksisites

ÖZTÜRK N., ÖZTÜRK D., PALA KARA Z., KAPTAN E., SANCAR BAŞ S., ÖZSOY N., et al.

24. Ulusal Farmakoloji Kongresi, Turkey, 17 - 20 October 2017, (Summary Text)

14. Fare Per2::Luc Hepa1-6 hepatokarsinoma hücre kültürlerinde sirkadiyan Per2 gen ekspresyon profilinin hücre konfluens oranına göre değişimi

ÖZTÜRK N., Levi F., OKYAR A.

24. Ulusal Farmakoloji Kongresi, Trabzon, Turkey, 17 - 21 October 2017, pp.24, (Full Text)

15. mTOR inhibitörü everolimusun sirkadiyan saat sistemi üzerine etkisi ve farelerdeki kronotoksisitesi

ÖZTÜRK N., Öztürk D., PALA KARA Z., KAPTAN E., SANCAR BAŞ S., ÖZSOY N., et al.

24. Ulusal Farmakoloji Kongresi, Trabzon, Turkey, 17 October - 21 September 2017, pp.10, (Full Text)

16. Astım ve KOAH tedavisinde akılcı ilaç kullanımı ve eczacının rolü.

ÖZTÜRK N., Akyel Y. K., Ekşi E. Ş., UYDEŞ DOĞAN B. S., OKYAR A.

24. Ulusal Farmakoloji Kongresi, Trabzon, Turkey, 17 - 21 October 2017, pp.12, (Summary Text)

17. Effect of cell confluency on Per2 gene expression oscillatory profiles in synchronized mouse Per2::luc Hepa1-6 hepatocarcinoma cell cultures.

ÖZTÜRK N., OKYAR A.

2nd International Gazi Pharma Symposium Series (GPSS-2017), Ankara, Turkey, 11 - 13 October 2017, pp.10, (Full Text)

18. Effect of everolimus on circadian rhythms of rest-activity and liver Per2 gene expression in freely moving mice.

ÖZTÜRK N., OKYAR A.

2nd International Gazi Pharma Symposium Series (GPSS-2017), Ankara, Turkey, 11 - 13 October 2017, pp.12, (Full Text)

19. Relevance of dosing time for everolimus toxicity in respect to the circadian P-glycoprotein expression in Mdr1a::Luc mice.

ÖZTÜRK N., Li X., Giacchetti S., Lévi F., OKYAR A.

19th International Conference on Biomedicine and Medical Pharmacology (ICBMP 2017), Lizbon, Portugal, 17 - 18 August 2017, vol.4, no.8, pp.10, (Full Text)

20. Relevance of dosing time for everolimus toxicity on thyroid gland and hormones in mice.

Öztürk D., ÖZTÜRK N., PALA KARA Z., KAPTAN E., SANCAR BAŞ S., ÖZSOY N., et al.

19th International Conference on Biomedicine and Medical Pharmacology (ICBMP 2017), Lizbon, Portugal, 17 - 18 August 2017, vol.4, no.8, pp.12, (Full Text)

21. Consistent dosing-time dependent tolerability of everolimus (EV) in a pilot study in women with metastatic breast cancers (MBC) and in a mouse chronopharmacology investigation

Giacchetti S., Li X. M., Ozturk N., Cuvier C., Machowiak J., Arrondeau J., et al.

San Antonio Breast Cancer Symposium, San-Antonio, Northern Mariana Islands, 6 - 10 December 2016, vol.77, (Summary Text) Sustainable Development

22. Consistent dosing-time dependent tolerability of everolimus (EV) in a pilot study in women with metastatic breast cancers (MBC) and in a mouse chronopharmacology investigation.

Giacchetti S., Li X., ÖZTÜRK N., Cuvier C., Machowiak J., Arrondeau J., et al.

San Antonio Breast Cancer Symposium 2016 (SABCS 2016), Teksas, United States Of America, 6 - 10 December 2016, vol.77, no.4, pp.10, (Full Text) Sustainable Development

23. Relevance of everolimus dosing time and for toxicity and circadian clock effects in mice.

Li X., ÖZTÜRK N., Doan T., OKYAR A., Finkenstadt Rand B., Giacchetti S., et al.

7. Avrupa Farmakoloji Kongresi (EPHAR 2016 – 7th European Congress of Pharmacology), İstanbul, Turkey, 26 - 30 June 2016, pp.195, (Full Text)

24. P-glycoprotein mediated pharmacokinetic interaction between talinolol and barnidipine.

ÖZTÜRK N., Öztürk D., PALA KARA Z., OKYAR A.

7. Avrupa Farmakoloji Kongresi (EPHAR 2016 – 7th European Congress of Pharmacology), İstanbul, Turkey, 26 - 30 June 2016, pp.471, (Full Text)

25. The circadian timing system as a toxicity target of the anticancer mTOR inhibitor everolimus in mice.

ÖZTÜRK N., Öztürk D., PALA KARA Z., KAPTAN E., SANCAR BAŞ S., ÇINAR S., et al.

7. Avrupa Farmakoloji Kongresi (EPHAR 2016 – 7th European Congress of Pharmacology), İstanbul, Turkey, 26 June - 30 July 2016, pp.196, (Summary Text)

26. Circadian control of drug metabolism, detoxification and pharmacokinetics.

OKYAR A.

7. Avrupa Farmakoloji Kongresi (EPHAR-2016), İstanbul, Turkey, 26 - 30 June 2016, pp.194, (Full Text)

27. Dosing-Time Dependent Reproductive Toxicity of Everolimus in Male Mice.

ÖZTÜRK N., Öztürk D., PALA KARA Z., KAPTAN E., SANCAR BAŞ S., Li X., et al.

Society for Research of Biological Rhythms 2016 (SRBR 2016), Florida, Palm Harbor, United States Of America, 21 - 25 May 2016, pp.208, (Full Text)

28. Chronotoxicity of Everolimus on the Immune System.

Öztürk D., ÖZTÜRK N., PALA KARA Z., KAPTAN E., SANCAR BAŞ S., ÇINAR S., et al.

Society for Research of Biological Rhythms 2016 (SRBR 2016), Florida, Palm Harbor, United States Of America, 21 - 25 May 2016, pp.172-173, (Full Text)

29. Eczacılık Eğitiminde Kalitenin Geliştirilmesi ve Sürdürülmesinde Öğrenci ile Etkileşimin Önemi

PALA KARA Z., OKYAR A., TOPAL TANYILMAZ G., ALP YILDIRIM F. İ., KALELİ DURMAN D., ÇARÇAK YILMAZ N., et al.

1. Ulusal Eczacılık Eğitimi ve Akreditasyon Kongresi, Ankara, Turkey, 9 - 10 May 2016, pp.47, (Full Text)

30. İstanbul Üniversitesi Eczacılık Fakültesi’nde Klinik Eczacılık Uygulamaları

PALA KARA Z., ALP YILDIRIM F. İ., KALELİ DURMAN D., ÇARÇAK YILMAZ N., ÖZTÜRK N., OKYAR A., et al.

1. Ulusal Eczacılık Eğitimi ve Akreditasyon Kongresi, Ankara, Turkey, 9 - 10 May 2016, pp.36, (Full Text)

31. Hepatokarsinoma hücre kültüründe P-glikoproteinin sirkadiyan kontrolü

ÖZTÜRK N., Dulong S., Roche V., Li X., OKYAR A., Levi F.

23. Ulusal Farmakoloji Kongresi, Ankara, Turkey, 7 - 10 September 2015, pp.206-207, (Full Text)

32. P-GLİKOPROTEİN SUBSTRATI TALİNOLOLÜN DİŞİ VE ERKEK FARELERDEKİ FARMAKOKİNETİĞİ

Öztürk D., Pala Kara Z., OKYAR A.

23. Ulusal Farmakoloji Kongresi, Ankara, Turkey, 7 - 10 September 2015, pp.388, (Full Text)

33. Hayvan Deneylerinde Farmakolojik Prensipler

OKYAR A.

23. Ulusal Farmakoloji Kongresi, Ankara, Turkey, 7 - 10 September 2015, pp.65-67, (Full Text)

34. Chronomodulated Administration of Oxaliplatin plus Capecitabine (XELOX) as First Line Chemotherapy in Metastatic Colorectal Cancer Patients: Phase II Brunch Regimen Study.

Pilanci K. N., Saglam S., Okyar A., Yucel S., Kara Z. P., Ordu C., et al.

Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO) / Clinical Science Symposium on Predicting and Improving Adverse Outcomes in Older Adults with Cancer, Illinois, United States Of America, 29 May - 02 June 2015, vol.33, (Summary Text) Sustainable Development

35. Circadian control of P-glycoprotein in hepatocarcinoma cell cultures (Hepa1-6).

ÖZTÜRK N., Li X., OKYAR A., Levi F.

Congrès de la Société Francophone de Chronobiologie, Paris, France, 29 - 31 October 2014, pp.50, (Full Text)

36. Drug Transporters: Circadian rhythms and therapeutic implications.

OKYAR A.

International Meeting on Pharmacy and Pharmaceutical Science, İstanbul, Turkey, 18 - 21 September 2014, pp.46, (Summary Text)

37. The circadian timing system as a toxicity target of the anticancer mTOR inhibitor everolimus in mice

ÖZTÜRK N., OKYAR A., Li X., Levi F.

17th World Congress of Basic and Clinical Pharmacology (WCP2014), Cape Town, South Africa, 13 - 18 July 2014, vol.115, no.1, pp.318, (Full Text) Sustainable Development

38. Transmucosal delivery of dimenhydrinate to rabbits employing mucoadhesive patch.

YILDIZ PEKÖZ A., OKYAR A., OCAK DEMİRCİ E. M., KAPTAN E., TEKELİ F., ERDAL M. S., et al.

9th World Meeting on Pharmaceutics, Biopharmaceutics and Pharmaceutical Technology,, Lizbon, Portugal, 31 March - 03 April 2014, pp.269-270, (Full Text)

39. P-glikoprotein substratı talinololün faredeki kronofarmakokinetiği.

PALA KARA Z., ÖZTÜRK N., Filipski E., Orman M., Levi F., OKYAR A.

22. Ulusal Farmakoloji Kongresi, Antalya, Turkey, 4 - 07 November 2013, pp.88, (Full Text)

40. P-glikoproteinin tümördeki ritimlerinin in vitro incelenmesi.

ÖZTÜRK N., OKYAR A., Van Der Horst B., Levi F.

22. Ulusal Farmakoloji Kongresi, Antalya, Turkey, 4 - 07 November 2013, pp.195, (Full Text)

41. Circadian and sex-dependent rhythms in P-glycoprotein expression and function in mice

OKYAR A., Filipski E., Piccolo E., ÖZTÜRK N., PALA KARA Z., Levi F.

XIII Congress of the European Biological Rhythms Society, Münih, Germany, 18 - 22 August 2013, pp.139-140, (Full Text)

42. Effect of Amaranthus lividus against carbon tetrachloride-induced kidney damage in rats

YILMAZ ÖZDEN T., CAN A., PALA KARA Z., OKYAR A.

19th International Symposium on Microsomes and Drug Oxidations-12th European Regional ISSX Meeting, Noordwijk Aan Zee, Netherlands, 17 - 21 June 2012, pp.139, (Full Text)

43. Barnidipin ve talinolol arasındaki P-glikoproteine bağlı olası bir farmakokinetik etkileşmenin incelenmesi

ÖZTÜRK N., PALA KARA Z., OKYAR A.

21. Ulusal Farmakoloji Kongresi (Türk Farmakoloji Derneği), Eskişehir, Turkey, 19 - 22 October 2011, pp.407, (Full Text)

44. The assessment of the work in the last three years of Istanbul University Local Ethical Committee for Animal Experiments

Kaymaz F. A., Yaltırık M., Dikmen Tekeli F., Yamantürk Çelik A. P., Belce A., Armutak A., et al.

3rd East Mediterranean International Council for Laboratory Animal Science (ICLAS) Symposium & XV. General Assembly, İstanbul, Turkey, 10 - 12 June 2011, pp.126, (Summary Text)

45. Protective activity of Amaranthus lividus L. against acute hepatotoxicity in rats

Ozden T. Y., Kara Z. P., Okyar A., Can A.

36th FEBS Congress of the Biochemistry for Tomorrows Medicine, Torino, Italy, 25 - 30 June 2011, vol.278, pp.320, (Summary Text)

46. Hepatoprotective effect of Smilax excelsa L.

ÖZSOY N., OKYAR A., CAN A., AKEV N., Baktır G.

The 2nd International Symposium on Medicinal Plants, Their Cultivation and Aspects of Uses, Jordan, 1 - 04 November 2010, pp.36-37, (Full Text)

47. Effect of Smilax excelsa L. on the antioxidant system in kidney tissue

ÖZSOY N., OKYAR A., AKEV N., CAN A., Baktır G.

The 2nd International Symposium on Medicinal Plants, Their Cultivation and Aspects of Uses, Jordan, 1 - 04 November 2010, pp.37-38, (Full Text)

48. Morphological and biochemical investigations of Amaranthus lividus L. in CCl4-induced liver injury rat models

YILMAZ ÖZDEN T., CAN A., SANCAR BAŞ S., PALA KARA Z., OKYAR A., BOLKENT Ş.

IMC17, The 17th IFSM International Microscopy Congress, Brazil, 1 - 04 September 2010, pp.0-25, (Full Text)

49. Vers l'optimisation de l'administration d'un agent anticancereux: etude experimentale et mathematique de la pharmacocinetique-pharmacodynamie de l'Irinotecan et de son controle par l'horloge circadienne

Ballesta A., Dulong S., OKYAR A., Levi F.

42. Fransızca Konuşulan Ülkeler Kronobiyoloji Derneği Kongresi, France, 1 - 04 September 2010, pp.38, (Summary Text)

50. Circadian changes in abcc2 expression in mouse ileum.

OKYAR A., Ahowesso C., Filipski E., Piccolo E., Tinari N., Iacobelli S., et al.

42. Fransızca Konuşulan Ülkeler Kronobiyoloji Derneği Kongresi, France, 1 - 04 September 2010, pp.39, (Summary Text)

51. Effect of Smilax excelsa L. leaf extract on liver injury in rats

ÖZSOY N., ARDA_PİRİNÇÇİ P., OKYAR A., BOLKENT Ş., AKEV N., Baktır G., et al.

The 17th IFSM International Microscopy Congress (IMC 17), Brazil, 1 - 04 September 2010, pp.0-24, (Full Text)

52. Antioxidant Effect of Amaranthus lividus L. Against CCl4-induced Hepatotoxicity in Rats

Yilmaz T., Can A., Pala Z., Okyar A.

9th International Meeting of the International-Society-for-the-Study-of-Xenobiotics(ISSX), İstanbul, Turkey, 4 - 08 September 2010, vol.42, pp.242-243, (Summary Text)

53. The CDK inhibitor roscovitine (Seliciclib) is a selective substrate of human P-glycoprotein (P-gp/ABCB1/MDR1)

Rajnai Z., Mehn D., Beery E., Okyar A., Jani M., Fulop F., et al.

9th International Meeting of the International-Society-for-the-Study-of-Xenobiotics(ISSX), İstanbul, Turkey, 4 - 08 September 2010, vol.42, pp.299-300, (Summary Text)

54. The effect of terpenes on skin absorption of tiaprofenic acid gel ex vivo and in vivo in rats

PALA KARA Z., Nuriyev M., YILDIZ PEKÖZ A., ÖZTÜRK N., OKYAR A.

16. IUPHAR Dünya Farmakoloji Kongresi (International Union of Pharmacology, 16th World Congress on Basic and Clinical Pharmacology 2010), Kopenhag, Denmark, 17 - 23 July 2010, pp.210, (Full Text)

55. Preclinical model for the personalization of cancer chronotherapeutics.

Ahowesso C., Li X., Dulong S., Filipski E., OKYAR A., Levi F.

XI. Avrupa Biyolojik Ritimler Derneği Kongresi, France, 1 - 04 August 2009, pp.209, (Full Text) Sustainable Development

56. Rhytmic intestinal drug elimination via ABC transporters: a potential determination of anticancer drug chronopharmacology

OKYAR A., Filipski E., Ahowesso C., Dulong S., Levi F.

XI. Avrupa Biyolojik Ritimler Derneği Kongresi, France, 1 - 04 August 2009, pp.153, (Summary Text)

57. Rhytmic intestinal drug eliminaion via ABC transporters: a potential determination of anticancer drug chronopharmacology

OKYAR A., Filipski E., Ahowesso C., Levi F., Dulong S., Delaunay F.

PROUST (The Temporal Dimension of Functional Dynamics; Genes at work on time, Italy, 1 - 04 October 2008, pp.37, (Full Text)

58. Effect of terpens as penetration enhancers on percutaneous penetration of tiaprofenic acid through pig skin

OKYAR A., YILDIZ PEKÖZ A., AKSU B., OZSOY Y., Baktır G.

6th World Meeting on Pharmaceutics, Biopharmaceutics and Pharmaceutical Technology, Barselona, Spain, 7 - 10 April 2008, pp.11-12, (Full Text)

59. Circadian changes in intestinal secretion: Drug-drug interactions with the P-glycoprotein (P-gp) substrate talinolol

Okyar A., Baktir G., Spahn-Langguth H.

49th Annual Meeting of the German-Society-for-Experimental-and-Clinical-Pharmacology-and-Toxicology, Mainz, Germany, 11 - 13 March 2008, vol.377, pp.62, (Summary Text)

60. Prediabetes screening program: A Proactive study in İstanbul community pharmacies

Cakiroglu ., Koroglu A., Öztosun Z., Dundar ., OKYAR A., ALP YILDIRIM F. İ., et al.

ESCP (European Society of Clinical Pharmacy) 36th European Symposium on Clinical Pharmacy, İstanbul, Turkey, 25 - 27 October 2007, pp.1, (Full Text)

61. Self management of complications in diabetic patients: a pharmaceutical care program in community pharmacies

Koroglu A., Cakiroglu ., Oztosun Z., Dundar ., ALP F. İ., OKYAR A., et al.

ESCP (European Society of Clinical Pharmacy) 36th European Symposium on Clinical Pharmacy, İstanbul, Turkey, 25 - 27 October 2007, pp.10, (Summary Text) Sustainable Development

62. P-glikoprotein (P-gp) substratları arasındaki ilaç-ilaç etkileşmeleri: P-gp'ye bağımlı intestinal sekresyondaki gece-gündüz farklılığının talinololün farmakokinetiğine etkisi

OKYAR A.

19. Ulusal Farmakoloji Kongresi, Trabzon, Turkey, 1 - 04 October 2007, pp.12, (Full Text)

63. Pre-diabetes screening program: A proactive study in Istanbul community pharmacies

Çakıroğlu A., Köroğlu A., Öztosun Z., Dündar A., OKYAR A., Alp İ., et al.

36th European Symposium on Clinical Pharmacy, Implementing Clinical Pharmacy in Community and Hospital Settings: Sharing the Experience, Turkey, 1 - 04 October 2007, pp.10, (Summary Text) Sustainable Development

64. Self-management of complications in diabetic patients: a pharmacetical care program in community pharmacies.

Köroğlu A., Çakıroğlu A., Öztosun Z., Dündar A., OKYAR A., Alp İ., et al.

65. in vitro and in vivo studies on ondansetron HCl loaded biodegradable mıcrospheres

ERGİNER Y., GÜNGÖR S., OKYAR A., TOKER S., Baktır G.

Pharmaceutical Sciences World Congress, Amsderdam, Netherlands, 22 - 25 April 2007, pp.1, (Full Text)

66. Vücutta Parçalanabilen Heparin Mikrokürelerinin Nazal Yol ile Uygulanması

ERGİNER Y., YILDIZ PEKÖZ A., OKYAR A., Baktır G., ARAMAN A. O.

VI. Ulusal Tromboz, Hemostaz ve Anjiolojik Kongresi, İzmir, Turkey, 5 - 07 May 2006, pp.1, (Full Text)

67. Deneysel diabette Aloe vera’nın pankreas dokusu üzerine etkisi

AKEV N., CAN A., BOLKENT H. S., BOLKENT Ş., YANARDAĞ R., OKYAR A.

XVIII. Ulusal Kimya Kongresi, Kars, Turkey, 1 - 04 July 2004, pp.513, (Full Text) Sustainable Development

68. Deneysel diabette Aloe vera’nın lipid profili üzerine etkisi

CAN A., AKEV N., ÖZSOY N., YANARDAĞ R., OKYAR A.

XVIII. Ulusal Kimya Kongresi, Kars, Turkey, 1 - 04 July 2004, pp.514, (Full Text) Sustainable Development

69. In vitro and In vivo Evaluation of Ciprofloxacin HCl Loaded Chitosan Microspheres by Spray-Drying Method and In Vivo Evaluation for Nasal Administration

ERGİNER Y., GÜRCAN D., OKYAR A., KARAKOÇ B., BAKTIR G., GERÇEKER A.

European Conference on Drug Delivery and Pharmaceutical Technology, Sevilla, Spain, 10 - 12 May 2004, pp.1, (Full Text)

70. Circadian variation in effective permeabilities of talinolol and losartan in rats: Metabolism- or transport-related?

Lemmer B., Dressler C., Okyar A., Baktir G., Spahn-Langguth H.

45th Spring Meeting of the German-Society-for-Experimental-and-Clinical-Pharmacology-and-Toxicology, Mainz, Germany, 9 - 11 March 2004, vol.369, (Summary Text)

71. Biodegredable heparin microspheres: II. Nasal administration of heparin microspheres

ERGİNER Y., YILDIZ PEKÖZ A., OKYAR A., ARAMAN A. O., BAKTIR G.

5th International Conference and Workshop on Cell Culture and In-vitro models for Drug Absorption and Delivery, Saarbrücken, Germany, 25 February - 05 March 2004, pp.1, (Full Text)

72. Circadian variation of effective permeabilities of talinolol and losartan in rats. Metabolism –or transport- related?

OKYAR A., Derssler C., Hanafy A., Baktır G., Lemmer B., Spahn-Langguth H.

XVII. Ulusal Farmakoloji Kongresi, 1. Klinik Farmakoloji Sempozyumu ve Türk-Hollanda Farmakoloji Dernekleri Ortak Toplantısı, Antalya, Turkey, 1 - 04 October 2003, pp.197, (Full Text)

73. Effect of Aloe vera on skin lipid peroxidation in type-II diabetic rats

AKEV N., ÖZSOY N., CAN A., YANARDAĞ R., OKYAR A.

3 rd International Symposium on Natural Drugs Proceedings, Italy, 1 - 04 October 2003, pp.17-19, (Full Text) Sustainable Development

74. Effect of simvastatin on talinolol pharmacokinetics

PALA KARA Z., OKYAR A., Spahn-Langguth H., Baktır G.

XVII. Ulusal Farmakoloji Kongresi, 1. Klinik Farmakoloji Sempozyumu ve Türk-Hollanda Farmakoloji Dernekleri Ortak Toplantısı, Antalya, Turkey, 1 - 04 October 2003, pp.92, (Full Text)

75. Effect of P-glycoprotein inhibitor atorvastatin on absorption and distribution of talinolol

OKYAR A., PALA KARA Z., Spahn-Langguth H., Baktır G.

XVII. Ulusal Farmakoloji Kongresi, 1. Klinik Farmakoloji Sempozyumu ve Türk-Hollanda Farmakoloji Dernekleri Ortak Toplantısı, Antalya, Turkey, 1 - 04 October 2003, pp.88, (Full Text)

76. Effect of Aloe vera leaf gel and pulp extracts on serum lipid parameters and heart tissue lipid peroxidation in type-II diabetic rats

CAN A., AKEV N., ÖZSOY N., YANARDAĞ R., OKYAR A.

3 rd International Symposium on Natural Drugs Proceedings, Italy, 1 - 04 October 2003, pp.17-19, (Full Text) Sustainable Development

77. The effect of Aloe vera (L.) Burm Fil., on the antioxidant system in lenses of type-II diabetic rats

Ozsoy N., YANARDAĞ R., Can A., Akev N., Okyar A.

Proccedings of ICNP-2002, Trabzon, Turkey, 1 - 04 October 2002, pp.263-266, (Full Text) Sustainable Development

78. The effect of Aloe vera (L.) Burm. fil. on the antioxidant system in lenses of type-II diabetic rats

ÖZSOY N., YANARDAĞ R., CAN A., AKEV N., OKYAR A.

1 st International Congress on the Chemistry of Natural Products (ICNP), TRABZON, Turkey, 1 - 04 October 2002, pp.0-66, (Full Text) Sustainable Development

79. The effect of Aloe vera (L.) Burm. fil. leaf gel and pulp extracts on the kidney in type-II diabetic rat models: A histological and biochemical study

BOLKENT Ş., AKEV N., ÖZSOY N., İNCELİ M., CAN A., OKYAR A., et al.

VI th Plant Life of Southwest Asia Symposium, Yüzüncü Yıl University, VAN, Turkey, 1 - 04 June 2002, pp.48, (Full Text) Sustainable Development

80. The effect of Aloe vera (L.) Burm. fil leaf gel and pulp extracts on the liver in type-II diabetic rat models:a biochemical study.

CAN A., AKEV N., ÖZSOY N., YANARDAĞ R., OKYAR A.

VIth Plant Life of Southwest Asia Symposium, Turkey, 1 - 04 June 2002, pp.50, (Full Text) Sustainable Development

81. The effect of Aloe vera (L.) Burm. Fil. leaf gel and pulp extracts on the kidney in type-II diabetic rat models: A histological and biochemical study

Bolkent Ş., Akev N., Özsoy N., Şengezer İnceli M., Can A., Okyar A., et al.

VIth Plant Life of Southwest Asia Symposium, Turkey, 1 - 04 June 2002, pp.48, (Full Text) Sustainable Development

82. Drug-drug interactions with P-glycoprotein substrates: Mechanism for AUC increase is different for p.o. and i.v. vinblastine coadministration?

OKYAR A., Hanafy A., Baktır G., Spahn-Langguth H.

Deutsche Gesellschaft für experimentelle und klinische Pharmakologie und Toxikologie, 42. Spring Meeting, Germany, 1 - 04 March 2001, pp.0-115, (Full Text)

83. Aloe vera yapraklarının tip II diabetik sıçanların kan şekeri düzeyine etkisi (kronik deneyler)

OKYAR A., AKEV N., CAN A., Baktır G., SÜTLÜPINAR N.

XIII. Bitkisel İlaç Hammaddeleri Toplantısı, Bildiri Kitabı, Marmara Üniv. Yayın No. 670, Ecz. Fak. Yayın No. 17, İstanbul, Turkey, 1 - 04 January 2001, pp.281-286, (Full Text) Sustainable Development

84. Aloe vera yapraklarının tip II diabetik sıçanların kan şekeri düzeyine etkisi (kronik deneyler).

OKYAR A., CAN A., AKEV N., Baktır G., SÜTLÜPINAR N.

XIII. Bitkisel İlaç Hammadeleri Toplantısı, İstanbul, Turkey, 1 - 04 September 2000, pp.67, (Full Text) Sustainable Development

85. Aloe vera yapraklarının tip II diabetik sıçanların kan şekeri düzeyine etkisi (kronik deneyler)

OKYAR A., CAN A., AKEV N., Baktır G., SÜTLÜPINAR N.

XIII. Bitkisel İlaç Hammadeleri Toplantısı, İstanbul, Turkey, 1 - 04 September 2000, pp.0-67, (Full Text) Sustainable Development

86. Aloe vera yapraklarının tip I ve tip II diabetik sıçanların kan glukoz düzeyine etkisi.

OKYAR A., CAN A., AKEV N., SÜTLÜPINAR N., Baktır G.

Türk Farmakoloji Derneği XV. Ulusal Farmakoloji Kongresi, Antalya, Turkey, 1 - 04 November 1999, pp.7-4, (Full Text) Sustainable Development

87. Terfenadinin genç deneklerde psikomotor performansa etkisi

Hocaoğlu N., OKYAR A., Baktır G.

XV. Ulusal Farmakoloji Kongresi, Aydın, Turkey, 1 - 04 November 1999, pp.12-13, (Full Text)

88. Effect of Aloe vera leaves on blood glucose level in type-I and type-II diabetic rat models.

OKYAR A., CAN A., AKEV N., Baktır G., SÜTLÜPINAR N.

2000 Years of Natural Products Research - Past, Present and Future, Netherlands, 1 - 04 July 1999, pp.51, (Full Text) Sustainable Development

89. Effect of Aloe vera leaves on blood glucose level in type-I and type-II diabetic rat models

OKYAR A., CAN A., AKEV N., Baktır G., SÜTLÜPINAR N.

2000 Years of Natural Products Research – Past, Present and Future, Netherlands, 1 - 04 July 1999, pp.51, (Full Text) Sustainable Development

90. Setirizinin psikomotor performansa etkisinin psikometrik testlerle incelenmesi

OKYAR A., Baktır G.

XIV. Ulusal Farmakoloji Kongresi ve ‘Angiotensin-II Receptor Antagonists in Cardiovascular Disease’ Sempozyumu, Antalya, Turkey, 1 - 04 November 1997, pp.772-777, (Full Text)

Books 3

Other Publications 5

Metrics

Publication

172

Publication (WoS)

Publication (Scopus)

H-Index (WoS)

Citation (Scopus)

2185

H-Index (Scopus)

Citation (Scholar)

3389

H-Index (Scholar)

Citation (TrDizin)

H-Index (TrDizin)

Citation (Sobiad)

H-Index (Sobiad)

Citation (Sum Other)

Project

Thesis Advisory

Open Access

UN Sustainable Development Goals

Publications & Works